EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.

Chen, Lin; He, Jiang; Zhou, Jianhua; Xiao, Zhi; Ding, Nianhua; Duan, Yumei; Li, Wenzheng; Sun, Lun-Quan

Chen, Lin; He, Jiang; Zhou, Jianhua; Xiao, Zhi; Ding, Nianhua; Duan, Yumei; Li, Wenzheng; Sun, Lun-Quan.

Affiliation

Chen L; Center for Molecular Medicine, Xiangya Hospital, Collaborative Innovation Center for Cancer Medicine, Central South University, Changsha, Hunan, P.R. China.
He J; Key Laboratory of Molecular Radiation Oncology, Changsha, Hunan, P.R. China.
Zhou J; Center for Molecular Medicine, Xiangya Hospital, Collaborative Innovation Center for Cancer Medicine, Central South University, Changsha, Hunan, P.R. China.
Xiao Z; Key Laboratory of Molecular Radiation Oncology, Changsha, Hunan, P.R. China.
Ding N; Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Duan Y; Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Li W; Center for Molecular Medicine, Xiangya Hospital, Collaborative Innovation Center for Cancer Medicine, Central South University, Changsha, Hunan, P.R. China.
Sun LQ; Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.

J Cell Mol Med ; 23(9): 6060-6071, 2019 09.

Article de En | MEDLINE | ID: mdl-31211507

Sujet(s)
Mots clés

EIF2A; ISR; chemotherapy; drug resistance; redox

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Facteur-2 d'initiation eucaryote / Paclitaxel / Protein-Serine-Threonine Kinases / EIF-2 Kinase Type d'étude: Prognostic_studies Limites: Female / Humans Langue: En Journal: J Cell Mol Med Sujet du journal: BIOLOGIA MOLECULAR Année: 2019 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google